1
Teva issued a voluntary recall for two lots of its hypertension drug Matzim LA
Indian generics company Sun Pharmaceuticals is facing yet another quality control issue as it recalls several lots of its blood pressure
J
SterRx, LLC today announced the voluntary nationwide recall of approximately 240 lots within their expiry period due to
Drug manufacturer Pfizer announced a voluntary recall of some types of blood pressure drugs in March and April 2022
The recall is categorized as Class 2 category, meaning that the use of the product may cause temporary or medically reversible adverse health consequences, with a remote probability of
Atorvastatin oral tablet dosage and frequency will depend upon several factors, the most important being the medical condition it is being targeted for and Diltiazem hydrochloride is a white to off-white crystalline powder with a bitter taste
Recall Guide is February 14, 2023
Indian generics company Sun Pharmaceuticals is facing yet Health Canada is advising that all lots of Marcan's diltiazem [MAR-Diltiazem CD 120, 180, 240 and 300mg capsules] are being recalled in Canada because of concerns that data submitted by Panexcell Clinical Laboratories for bioequivalence studies may have been falsified, resulting in potentially incorrect dosing
Search
Drugmaker Pfizer issued a voluntarily recall of three prescription blood pressure medications — one name brand and two generics — due to the presence of elevated levels of a potentially cancer-causing impurity
98
The recall is due to an out of specification for TEVA-DILTIAZEM XC 360MG TAB 100 bottle dissolution result during stability testing
Diltiazem Hydrochloride Extended-Release Tablets are an extended-release formulation intended for once-a-day administration
) Do not exceed 20 mg simvastatin daily with: The Recalls, Market Withdrawals & Safety Alerts are available on FDA’s website for three years before being archived
2
This recall is now being extended to the Retail Level
Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%
Related Resources